Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EORTC CLTF 2021 | Latest developments in PTCL treatment

Marta Rodriguez-Moreno • 11 Oct 2021
EORTC CLTF 2021
Lymphoma Non-Hodgkin Lymphoma Peripheral T-Cell Lymphoma Rare Diseases

Marta Rodriguez-Moreno, Instituto de Investigación Sanitaria, Fundación Jiménez Díaz University Hospital, Madrid, Spain, talks on recent research in peripheral T-cell lymphoma (PTCL), highlighting efforts to personalize treatments for patients with PTCL through the identification of new biomarkers. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Marta Rodriguez-Moreno

Prognostic factors for AITL 0:38
Prognostic factors for AITL
Marta Rodriguez-Moreno • 11 Oct 2021
Risk stratification of patients with PTCL using molecular profiling 4:24
Risk stratification of patients with PTCL using molecular profiling
Marta Rodriguez-Moreno • 11 Oct 2021

Related Videos

Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas 1:57
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam • 8 Dec 2025
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL 1:14
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam • 8 Dec 2025
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL 3:07
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
Lorenzo Falchi • 6 Dec 2025
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL 3:05
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL
Adam Olszewski • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals